Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
$20.74
-$0.09(-0.52%)
At close: 4:00 PM EST
$20.74
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$13.40 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.84M
Market Cap
$3.54B
Enterprise Value$3.41B
Total Cash (Recent Filing)$819.69M
Total Debt (Recent Filing)$52.19M
Price to Earnings (P/E)11.6
Beta1.12
Next Earnings
May 13, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.60
Shares Outstanding170,494,610
10 Day Avg. Volume1,867,919
30 Day Avg. Volume1,842,496
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.18
Enterprise Value/Gross Profit3.47
Enterprise Value/Ebitda25.95
Forecast
1Y Price Target
$32.53Price Target Upside56.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)0.45
Revenue Forecast (FY)$1.25B
Bulls Say, Bears Say
Bulls Say
Clinical Development CatalystsPivotal readouts for remlifanserin and mid‑stage data for the next‑generation compound represent potential catalysts if they show meaningful efficacy and a favorable safety profile compared with existing antipsychotic options.
Commercial Expansion And New FormulationExpansion of the Nuplazid and Daybue salesforces combined with the Daybue STIX powder formulation should broaden prescriber reach and increase patient access by addressing prior tolerability and administration barriers.
Valuation Upside From Approved ProductsStrong commercial performance of Nuplazid and Daybue and signs of untapped market uptake support an analyst view that existing approved products and the pipeline may be underappreciated by the market.
Bears Say
European Regulatory Negative OpinionA negative opinion from the European regulator and the limited scope for re‑examination create delays and significant uncertainty for European commercialization of the Rett syndrome and Daybue therapies.
Rebate And Revenue VolatilityUnexpected rebate adjustments have reduced reported Nuplazid sales and create the risk of continued revenue volatility if rebate dynamics persist or widen.
Rising Operating ExpensesPlanned increases in selling and administrative spending to expand the commercial footprint and higher research investment will elevate near‑term costs and pressure profitability metrics.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $13.40 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.54B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 51 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported $1.6 earnings per share for the quarter, beating the consensus estimate of $0.137 by $1.463.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 170,494,610 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $1.6 in its last earnings report, beating expectations of $0.137. Following the earnings report the stock price went down -1.322%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.53 (56.85% Upside)
$32.53 (56.85% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 149.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.72%
12-Months-Change
Fundamentals
Return on Equity
41.90%
Trailing 12-Months
Asset Growth
31.69%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACAD Company Deck
ACAD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and clear growth drivers: record adjusted revenue (> $1 billion), double-digit growth for both NUPLAZID and DAYBUE, an approved new DAYBUE formulation (STIX) with early traction, meaningful pipeline catalysts (remlifanserin Phase II readout in Aug–Oct 2026 and multiple planned study initiations), and a solid cash position. Offsetting these positives were industry- and company-specific risks: a negative CHMP trend vote for trofinetide in the EU creating regulatory uncertainty, a nonrecurring $20M IRA-related net sales adjustment plus cash outflows from IRA invoices, and a notable step-up in SG&A that will pressure near-term margins. On balance, the highlights — notably strong top-line growth, product launches, pipeline catalysts, and healthy cash — outweigh the lowlights, which are largely regulatory and timing risks.View all ACAD earnings summariesACAD Stock 12 Month Forecast
Average Price Target
$32.53
▲(56.85% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
Arcellx Inc
―
Ownership Overview
Currently, No data available
---